Express News | Pharvaris NV : Leerink Partners Cuts Target Price to $28 From $30

ReutersJan 20 10:59 ET

BofA Securities Maintains Pharvaris(PHVS.US) With Sell Rating, Maintains Target Price $14

Moomoo NewsJan 16 08:31 ET · Ratings

Bank of America Securities Sticks to Their Sell Rating for Pharvaris (PHVS)

TipRanksJan 16 07:35 ET · Ratings

Pharvaris Positioned for Growth: Strategic Focus on Deucrictibant and Financial Stability Drive Buy Rating

TipRanksJan 15 02:07 ET · Ratings

Pharvaris | 6-K: Report of foreign private issuer (related to financial reporting)

SECJan 13 07:27 ET · Announcements

Pharvaris Initiates Phase 3 Studies for Deucrictibant in Hereditary and Acquired Angioedema, Plans Strategic Developments for 2025

Quiver QuantitativeJan 13 07:01 ET